

BIOMARKERS AND TOXICITY MECHANISMS 10 – BIOMARKERS Introduction

Luděk Bláha, PřF MU, RECETOX www.recetox.cz

Tento projekt je spolufinancován Evropským sociálním fondem a státním rozpočtem České republiky.









INVESTICE DO ROZVOJE VZDĚLÁVÁNÍ

Definition and applications

 markers in biological systems with a sufficiently long half-life which allow location where in the biological system change occur and to quantify the change.

Various definitions and applications of "biomarkers"

- Ecology / Geology
- Human health and diseases
- Toxicology (special focus in this class)



Biomarkers in ECOLOGY / GEOLOGY





Biomarkers in HUMAN HEALTH



Nature Reviews | Drug Discovery



Biomarkers in HUMAN HEALTH ... a lot of work





Biomarkers in HUMAN HEALTH ... a lot of work

Overview of Multi-omic Approaches Applied in Biomarker Discovery





Biomarkers in TOXICOLOGY

- Identification of markers of long-term risks

- Human: health, toxicology and carcinogenesis
- Ecotoxicology: early markers of toxic effects
- BIOMARKER
 - Change which occurs as response to "stressors" (xenobiotics, disease, temperature...) extending the adaptive response beyond the normal range
- In vivo biomarkers:
 - changes measured in stressed organisms ("classical biomarkers")
- In vitro biomarkers
 - in vitro testing characterizing potencies of xenobiotic to induce specific biological activity (or toxicity mechanism)
 - = biological potencies (markers of potential hazards)



Biomarkers & Exposure

h: homeostatic conditionsc: reversible stager: irreversible effects of pollutants

Various biomarker profiles

- temporal changes-B2; B4
- repeated occurrence (B5)
- continuous increase (B1)
- increase with maximum (B3)

: B1 + B3 are candidate biomarkers !





Ideal biomarker





Centrum pro výzkum toxických látek v prostředí Biomarkers at different levels of biological organisation



Centrum pro výzkum toxických látek v prostředí

Biomarkers - classification

Categorization by US National Academy of Sciences

- Biomarkers of exposure
- Biomarkers of response or effect
- Biomarkers of susceptibility

Continuum exists among biomarkers

example: adducts of toxicant to DNA
? biomarker of exposure / ? response



Various biomarker types

Specific (selective) in vivo biomarkers

- Biomarkers selectively reflecting specific types (mechanisms) of toxicity
 - E.g. inhibition of AcCholE : exposure = organophosphates; effect = neurotoxicity
- + provides specific information
- multiple biomarkers must be measured in parallel

• Non-specific (non-selective) in vivo biomarkers

- Biomarkers of general stress
 - E.g. induction of Heat Shock Proteins (hsp)
- + general information about stress
- sensitive to many "stressors" (temperature, salinity ...)



Sampling biological materials for biomarker analyses

Non-destructive (non-invasive)

- blood / haemolymph collection & analyses
- skin, feather, hair ... (life of the organism not affected)

Destructive (invasive)

- whole animal
 - \rightarrow 3R principles: maximum use of the material
- multiple biomarker evaluation

GILLS Benzopyrene mono-oxygenase activity NADH ferricyanide reductase activity

Micronuclei (mutagenicity)

total proteins

HEPATOPANCREAS Benzopyrene mono-oxygenase activity Ethoxyresorufin-O-deethylase NADPH cytochrome c reductase NADH cytochrome c reductase SDS-PAGE for P450 Alkaline unwinding assay (DNA damage) Porphyrins Total proteins





HAEMOLYMPH Acetylcholinesterase activity Butycholinesterase activity Micronuclei **Total proteins**

EXAMPLE - Paracetamol





- paracetamol (1)
- (2)parent compound measurement - biomarker of exposure
- (3)activation to reactive metabolite (N-ac-p-benzoquinone, NAPQI) by CYP → reaction with GSH / measurement – levels of CYPs; levels of GSH – susceptibility
- (4) GSH-NAPQI conjugate – exposure, susceptibility
- NAPQI-protein adducts \rightarrow toxicity: **exposure**, effective dose (5)
- adaptations: GSH depletion, inhibition of protein synthesis **biomarkers of response** (6)
- (7)protein alkylation \rightarrow degeneration of hepatocytes: necrosis
 - \rightarrow increase concentrations of bilirubin in plasma + inflammation response / effect

Toxicity biomarkers – examples

Table 1 Examples of different biomarkers illustrated with specific examples and examples of the stressor which may result in the biomarker changes

Type of biomarker	Biomarker	Specific example	Stressor
Exposure	DNA adducts Protein adduct DNA fragments	Styrene oxide- <i>O</i> ⁶ guanine N ⁷ -Guanyl-aflatoxin B ₁ 7,8-Dihydro-8-oxoguanine	Styrene exposure Dietary aflatoxin Reactive oxygen species
Exposure and effect (response)	Protein adducts Enzyme inhibition Urinary metabolites	Carboxyhaemoglobin Acctylcholinesterase inhibition Mercapturic acids	CO inhalation Organophosphates Buta-1,3 diene, allyl chloride
Effect (response)	Serum/plasma enzymes	AST (aspartate aminotransferase) LDH (lactate dehydrogenase) ALT (alanine aminotransferase) ALP (alkaline phosphatase) CK or CPK (creatine kinase)	Xenobiotics causing necrosis Xenobiotics causing necrosis Hepatotoxic compounds Bile duct toxins Heart/muscle toxins
	Serum/plasma biochemistry	Urea (changes) Protein (reduced, e.g. albumin) Bilirubin	Hepatotoxic and nephrotoxic compounds Hepatotoxic compounds Liver injury
	Clotting time Urinary metabolites Raised antioxidant levels Enzyme induction Stress proteins Protective proteins Allergic response Histology Clinical observations Population studies	Prothrombin Glucose, raised creatinine, GSH conjugates Liver glutathione P450 induction hsp 60, hsp 70, hsp90 Metallothionein Antibodies, e.g. IgG Dermatitis Chromosomal aberrations, micronuclei Heart rate, temperature, sleeping time Breeding patterns, migrations	Warfarin (rodenticide) Pancreatic abnormalities, kidney damage Reactive oxygen species Polycyclic aromatic hydrocarbons Cadmium, heat Heavy metals, e.g. cadmium Antigens Nickel Genotoxic agents Barbiturates Climate change
Susceptibility	Phenotype Oncogenes	Acetylator phenotype (<i>NAT 2</i>) Dominant oncogenes (<i>ras. mic</i>) Recessive suppressor gene (<i>p52</i>)	
	'Cancer' genes	Breast-ovary cancer gene (BRCA 1)	



Other examples

Toxicity biomarkers



Centrum pro výzkum toxických látek v prostředí

Table 9.2 Availability of biomarkers in blood	Table	9.2	Availability	of	biomarkers	in	blood
---	-------	-----	--------------	----	------------	----	-------

Biomarker	Blood	Tissue of choice	Comment
AChE inhibition	+?	Brain	Effects in blood more transient
Neurotoxic esterases	-	Brain	Enzyme is limited to brain
Biogenic amines	-	Brain	Changes in blood too transient
DNA			
Strand breakage	?	Wide range	Nucleated avian red blood cells are possible
Adduct formation	+	Wide range	Haemoglobin is good substitute for DNA
SCE	+	Wide range	Blood lymphocytes can be used
Degree of methylation	?	Wide range	Nucleated avian red blood cells are possible
MFO	-	Liver	Western blotting technique on leucocytes is possible
Thyroid	+	Thyroid	Circulating levels of T_3 and T_4 are sensitive
Retinols	+	Liver	Advances to usc plasma are being made
Porphyrins	+?	Liver	Advances to use plasma are likely
ALAD	+	Blood	Tissue of choice
Enzymes	+	Blood	Tissue of choice
Immunotoxic	-	Lymphatic cells, bone marrow	Limited number of tests available for blood